anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Fevipiprant
Trial phase: Phase 2
SMILES: Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1C(F)(F)F
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 11
Group description: QAW039 75 mg Chewable tablet
Eligibility criteria:
Inclusion Criteria:

Children
Written informed consent by parent(s)/legal guardian(s) for the pediatric patient and assent by the pediatric patient (depending on local requirements) must be obtained before any study-specific assessment is performed.
Confirmed/documented diagnosis of asthma, as defined by national or international asthma guidelines for at least 6 months prior to study enrollment.
Subjects using asthma rescue medication (e.g. SABA) without asthma controller therapy or patients receiving daily treatment with a stable dose ICS (with or without additional controller such as long-acting β-agonists (LABA), long-acting muscarinic antagonists (LAMA)) for at least 4 weeks prior to Treatment Visit (Day 1).
Subjects must be able to attend study visits as per Study Visit Assessment Schedule (Section 8) which includes 8 to 9 hours in the clinic/home on the day of End of Treatment Visit and have blood draws as scheduled in the study.

Exclusion Criteria:

Use of other investigational drugs within 5 half-lives of enrollment, or (within 30 days (for small molecules)/until the expected pharmacodynamic effect has returned to baseline (for biologics)), whichever is longer.
Subject is unable to ingest banana and/or yogurt
History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes.
History of chronic lung disease other than asthma such as and not limited to, sarcoidosis interstitial lung disease, cystic fibrosis, mycobacterial or other infection (including active tuberculosis or atypical mycobacterial disease).
History of active bacterial, viral or fungal infection within 6 weeks of Treatment Visit (Day 1).
Intervention: Fevipiprant
Trial phase: Phase 2
SMILES: Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1C(F)(F)F
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 11
Group description: QAW039 375 mg Chewable tablet
Eligibility criteria:
Inclusion Criteria:

Children
Written informed consent by parent(s)/legal guardian(s) for the pediatric patient and assent by the pediatric patient (depending on local requirements) must be obtained before any study-specific assessment is performed.
Confirmed/documented diagnosis of asthma, as defined by national or international asthma guidelines for at least 6 months prior to study enrollment.
Subjects using asthma rescue medication (e.g. SABA) without asthma controller therapy or patients receiving daily treatment with a stable dose ICS (with or without additional controller such as long-acting β-agonists (LABA), long-acting muscarinic antagonists (LAMA)) for at least 4 weeks prior to Treatment Visit (Day 1).
Subjects must be able to attend study visits as per Study Visit Assessment Schedule (Section 8) which includes 8 to 9 hours in the clinic/home on the day of End of Treatment Visit and have blood draws as scheduled in the study.

Exclusion Criteria:

Use of other investigational drugs within 5 half-lives of enrollment, or (within 30 days (for small molecules)/until the expected pharmacodynamic effect has returned to baseline (for biologics)), whichever is longer.
Subject is unable to ingest banana and/or yogurt
History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes.
History of chronic lung disease other than asthma such as and not limited to, sarcoidosis interstitial lung disease, cystic fibrosis, mycobacterial or other infection (including active tuberculosis or atypical mycobacterial disease).
History of active bacterial, viral or fungal infection within 6 weeks of Treatment Visit (Day 1).
Intervention: Soticlestat
Trial phase: Phase 2
SMILES: O=C(c1cccnc1-c1ccncc1)N1CCC(O)(Cc2ccccc2)CC1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 71
Group description: TAK-935 tablets orally or via G-tube/PEG tube, BID. Participants weighing <60 kg received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
Eligibility criteria:
Inclusion Criteria:

Male and female participants aged greater than or equal to (>=) 2 and less than or equal to (<=) 17 years
Clinical diagnosis of DS or LGS
Weight of >=10 kilogram (kg) at the Screening visit
Currently taking 1 to 4 anti-epileptic drugs (AEDs) at a stable dose
Failed to become and remain seizure free with trials of at least 2 AEDs

Exclusion Criteria:

Has been admitted to a medical facility and intubated for treatment of status epilepticus 2 or more times in the 3 months immediately prior to the screening visit
Non-epileptic events that cannot be reliably distinguished from epileptic seizures
Participation in a clinical study involving another study drug in the previous month
Intervention: Tranexamic acid
Trial phase: Phase 4
ATC code: B02AA02
SMILES: NC[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 100
Group description: 10mg/kg intravenous tranexamic acid administered prior to surgical incision
Eligibility criteria:
Inclusion Criteria:

ASA (American Society of Anesthesiology) class I-IV
age 8-75.

Exclusion Criteria:

ASA class V
morbid obesity
patient refusal
patients with known coagulopathy disorder
renal insufficiency
hepatic dysfunction
serious cardiac disease
an allergy to TXA or receiving antiplatelet and /or anticoagulant drugs will be excluded.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 100
Group description: 10mg/kg intravenous normal saline administered prior to surgical incision
Eligibility criteria:
Inclusion Criteria:

ASA (American Society of Anesthesiology) class I-IV
age 8-75.

Exclusion Criteria:

ASA class V
morbid obesity
patient refusal
patients with known coagulopathy disorder
renal insufficiency
hepatic dysfunction
serious cardiac disease
an allergy to TXA or receiving antiplatelet and /or anticoagulant drugs will be excluded.
Intervention: Lidocaine
Trial phase: Phase 4
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 37
Group description: Lidocaine: Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
Eligibility criteria:
Inclusion Criteria:

Females above age 18 presenting to Duke Gynecology Oncology clinic for vulvar biopsy
Able to provide informed consent in English and agree to the risks of the study

Exclusion Criteria:

Not able to provide informed consent
Vulvar biopsy on a hair bearing surface
Intervention: Oraqix
Trial phase: Phase 4
SMILES: CCCNC(C)C(=O)Nc1ccccc1C.CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 37
Group description: EMLA: Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
Eligibility criteria:
Inclusion Criteria:

Females above age 18 presenting to Duke Gynecology Oncology clinic for vulvar biopsy
Able to provide informed consent in English and agree to the risks of the study

Exclusion Criteria:

Not able to provide informed consent
Vulvar biopsy on a hair bearing surface
Intervention: Gusacitinib
Trial phase: Phase 2
SMILES: N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 45
Group description: ASN002 40 mg

Daily dose of ASN002
Eligibility criteria:
Inclusion Criteria

Subject with a history of moderate to severe atopic dermatitis who participated in the preceding ASN002AD-201 and ASN002AD-101 study
Subject must be a candidate for prolonged open label ASN002/gusacitinib treatment according to the investigator's judgment.
Subject has been using an emollient daily for at least 1 week prior to Day 1 and agrees to continue using that same emollient daily throughout the study.
Men and women participating in the study must use medically acceptable birth control or total abstinence from sexual intercourse
Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.
Subjects must be willing to comply with all study procedures and must be available for the duration of the study.
Subject has a body mass index (BMI) ≤ 38 kg/m2.

Exclusion Criteria

Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
Subject has clinically infected atopic dermatitis.
A serious uncontrolled condition including hypertension, history of tuberculosis, hepatitis B or C infection, immune deficiency, heart disease, heart conduction disorder, diverticulitis, diabetes, reflux disease requiring protocol pump inhibitor therapy, malabsorption syndrome, or cancer
Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
Subject has a history of eczema herpeticum within 12 months, and/or a history of 2 or more episodes of eczema herpeticum in the past.
Willing to comply with discontinuation of certain treatments for AD, as directed by the Investigator.
Intervention: Gusacitinib
Trial phase: Phase 2
SMILES: N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 41
Group description: ASN002 60 mg

Daily dose of ASN002
Eligibility criteria:
Inclusion Criteria

Subject with a history of moderate to severe atopic dermatitis who participated in the preceding ASN002AD-201 and ASN002AD-101 study
Subject must be a candidate for prolonged open label ASN002/gusacitinib treatment according to the investigator's judgment.
Subject has been using an emollient daily for at least 1 week prior to Day 1 and agrees to continue using that same emollient daily throughout the study.
Men and women participating in the study must use medically acceptable birth control or total abstinence from sexual intercourse
Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.
Subjects must be willing to comply with all study procedures and must be available for the duration of the study.
Subject has a body mass index (BMI) ≤ 38 kg/m2.

Exclusion Criteria

Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
Subject has clinically infected atopic dermatitis.
A serious uncontrolled condition including hypertension, history of tuberculosis, hepatitis B or C infection, immune deficiency, heart disease, heart conduction disorder, diverticulitis, diabetes, reflux disease requiring protocol pump inhibitor therapy, malabsorption syndrome, or cancer
Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
Subject has a history of eczema herpeticum within 12 months, and/or a history of 2 or more episodes of eczema herpeticum in the past.
Willing to comply with discontinuation of certain treatments for AD, as directed by the Investigator.
Intervention: Gusacitinib
Trial phase: Phase 2
SMILES: N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 76
Group description: ASN002 80 mg

Daily dose of ASN002
Eligibility criteria:
Inclusion Criteria

Subject with a history of moderate to severe atopic dermatitis who participated in the preceding ASN002AD-201 and ASN002AD-101 study
Subject must be a candidate for prolonged open label ASN002/gusacitinib treatment according to the investigator's judgment.
Subject has been using an emollient daily for at least 1 week prior to Day 1 and agrees to continue using that same emollient daily throughout the study.
Men and women participating in the study must use medically acceptable birth control or total abstinence from sexual intercourse
Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.
Subjects must be willing to comply with all study procedures and must be available for the duration of the study.
Subject has a body mass index (BMI) ≤ 38 kg/m2.

Exclusion Criteria

Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
Subject has clinically infected atopic dermatitis.
A serious uncontrolled condition including hypertension, history of tuberculosis, hepatitis B or C infection, immune deficiency, heart disease, heart conduction disorder, diverticulitis, diabetes, reflux disease requiring protocol pump inhibitor therapy, malabsorption syndrome, or cancer
Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
Subject has a history of eczema herpeticum within 12 months, and/or a history of 2 or more episodes of eczema herpeticum in the past.
Willing to comply with discontinuation of certain treatments for AD, as directed by the Investigator.
Intervention: Acthargel
Trial phase: Phase 4
SMILES: CSCCC(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(N)CO)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1cnc[nH]1)C(=O)NC(Cc1ccccc1)C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCC(=O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(Cc1ccc(O)cc1)C(=O)N1CCCC1C(=O)NC(CC(N)=O)C(=O)NCC(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(Cc1ccccc1)C(=O)N1CCCC1C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)O)C(C)C)C(C)C)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Participants receive Acthar Gel
Eligibility criteria:
Inclusion criteria:

Is male or nonpregnant, nonlactating female
Has been diagnosed with current severe NIPPU

Has active disease at the Baseline Visit as defined by the presence of at least 1 of the following parameters in at least one eye despite at least 2 weeks of maintenance therapy with oral prednisone (or oral corticosteroid equivalent):

Has active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion
Has ≥ 2+ anterior chamber cells [Standardization of Uveitis Nomenclature (SUN) criteria]
Has ≥ 1.5+ vitreous haze
Is willing to taper current doses of corticosteroid and immunomodulatory therapy to the minimum effective dose during the study.
If under treatment with any immunosuppressants, immunomodulators, or biologic agents for a comorbid condition, has been on a stable dose for 2 weeks before screening

Exclusion criteria:

Has proliferative or severe nonproliferative diabetic retinopathy, clinically significant macular edema due to diabetic retinopathy, neovascular/wet age-related macular degeneration, abnormality of vitreoretinal interface with the potential for macular structural damage independent of the inflammatory process or severe vitreous haze that precludes visualization of the fundus at the Baseline Visit
Has Type 1 or Type 2 diabetes mellitus, tuberculosis, history of hepatitis, peptic ulcer, active infection, or any contraindication for treatment with Acthar Gel
Intervention: Racivir
Trial phase: Phase 3
ATC code: J05AF09 | J05AR03 | J05AR06 | J05AR08 | J05AR09 | J05AR17 | J05AR18 | J05AR19 | J05AR20 | J05AR22
SMILES: Nc1nc(=O)n(C2CSC(CO)O2)cc1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: HIV patients on stable therapy switching from Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) to the Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
Eligibility criteria:
Inclusion Criteria:

Patients with HIV on abacavir/lamivudine/dolutegravir STR regimens for at least 1 year fulfilling the following inclusion criteria:

age ≥ 45 years for men and ≥ 55 years for women;
at least one coronary risk factor including smoking, dyslipidemia, hypertension, obesity (BMI >30) or diabetes, or a calculated 10-year risk of heart attack of 7.5% or higher;
HIV RNA < 200 copies/mL at last clinical measurement, done within the past 12 months prior to screening, with no intervening HIV RNA > 200;
Screening HIV RNA < 50 copies/mL, CBC, and chemistries that, in the judgment of the investigator, do not preclude the use of Biktarvy.

Exclusion Criteria:

patients not fulfilling inclusion criteria;
unstable HIV disease or other medical condition that, in the opinion of the investigator, would interfere with the conduct of the study;
history of cardiomyopathy (LVEF <40%) or significant valvular heart disease;
cirrhosis;
end stage renal disease on dialysis;
uncontrolled hypertension (defined as SBP >200 or DBP >110);
pregnancy;
Patients requiring medications contraindicated with the components of B/F/TAF;
Patients on active treatment for severe asthma or severe COPD.
Intervention: Mitomycin
Trial phase: Phase 2
ATC code: L01DC03
SMILES: [H][C@]12N[C@@]1([H])CN1C3=C(C(=O)C(N)=C(C)C3=O)[C@@H](COC(N)=O)[C@]12OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: Mitomycin c: All participants will receive a single 40 mg dose of mitomycin C intraoperatively during their scheduled nephroureterectomy. This single dose will be given through a catheter in the subject's bladder.
Eligibility criteria:
Inclusion Criteria:

Both males and females ≥ eighteen years of age
Clinical diagnosis of urothelial carcinoma of the renal pelvis and/or ureter. Clinical diagnosis of urothelial carcinoma may be based upon radiographic, pathologic or cytological findings alone or in combination with one another. No other histology is allowed.
The TNM stage of the subject's disease (using the American Joint Committee on Cancer [AJCC] Cancer Staging Manual, 8th Edition) must be Tis, Ta, T1, T2, or T3, N0, M0. Subjects may have either a high-grade or low-grade tumor.
ECOG performance status of 0-2
Written informed consent obtained from the subject and the ability for the subject to comply with all the study-related procedures.
Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy prior to and for at least 3 months after mitomycin C instillation to minimize the risk of pregnancy. Prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.
Males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) should avoid conceiving children prior to and for 3 months following mitomycin C instillation
Subjects must have hemoglobin ≥ 9 g/dL and a platelet count ≥ 100,000/μL.

Exclusion Criteria:

Active urothelial carcinoma of the bladder within 12 months prior to enrollment
History of adverse reaction to mitomycin C
Evidence of regional or metastatic disease.
History of radical cystectomy
Planned radical cystectomy at the time of nephroureterectomy
Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy prior to and for at least 3 months after mitomycin C instillation.
Females who are pregnant or breastfeeding.
History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
Prisoners or subjects who are involuntarily incarcerated.
Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
Subjects demonstrating an inability to comply with the study and/or follow-up procedures
Intervention: Cefixime
Trial phase: Phase 2
ATC code: J01DD08 | J01RA15 | J01RA16
SMILES: C=CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(=NOCC(=O)O)c3csc(N)n3)C2SC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Patients of the "Cefixime Group" will receive Cefixime 400 mg, per os, one tablet, two times per day, for ten consecutive days. The study team will provide the medication.

The group will consist of 50 patients.

Cefixime 400 milligram Oral Capsule [Suprax]: The intervention group will receive Cefixime 400mg, one tablet twice per day, for ten consecutive days
Eligibility criteria:
Inclusion Criteria:

18 years of age or older and able to provide informed consent
Cases of primary, secondary or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment.
HIV infected individuals willing to participate in the study must have CD4 count ≥350 cells/μl within the last 4 weeks and be virally suppressed (i.e., viral load ≤ 200 copies/mL) for HIV for the 6 months prior to enrolment with the most recent results within the last 4 weeks. inclusion
Non-cephalosporin allergic
Able to travel to the clinic once a day or be available for phone calls or receive text messages for at least 7-10 days and willing to attend follow-up visits
Able to swallow pills

Exclusion Criteria:

Pregnancy or positive pregnancy test
Serofast RPR titer (prior titer 1:8 or greater)
Recent (less than 7 days) or concomitant antimicrobial therapy with activity against syphilis.
Cephalosporin allergy: previous episode of flushing, urticaria, angioedema, rhinitis, bronchospasm, and anaphylactic shock, rash after taking cephalosporin.
Penicillin allergy: previous episode of flushing, urticaria, angioedema, rhinitis, bronchospasm, and anaphylactic shock, rash after receiving Penicillin.
Has a medical condition or other factor that might affect their ability to follow the protocol
Intervention: Basaglar
Trial phase: Phase 4
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)N3CCCC3C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NCC(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: BI group will receive only one injection of insulin glargine in the morning.

Insulin Glargine: 0.40 units/kg body weight
Eligibility criteria:
Inclusion Criteria:

-Age >65 years

Exclusion Criteria:

Unable to provide informed consent
Enrollment in another research study
History of hypoglycemia unawareness
Pregnant women
Prisoners